Profile
Felix Geissler served as Vice President-Medical Affairs at Curis, Inc. in 2022-2023.
Prior to that, he held the same position at Horizon Therapeutics Plc.
He also served as Chief Medical Officer at Lumicell, Inc. and as SVP, Head-Oncology, Hematology & Transplant at Sanofi Corp.
Geissler holds a doctorate degree from the University of Innsbruck, Eberhard Karls Universität Tübingen, and Ludwig-Maximilians-Universität München.
Former positions of Felix Geissler
| Companies | Position | End |
|---|---|---|
| CURIS, INC. | Chief Tech/Sci/R&D Officer | 2022-12-31 |
| Sanofi Corp. | Corporate Officer/Principal | - |
Lumicell, Inc.
 Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Lumicell, Inc. develops and markets image-guided cancer surgery solutions. It offers Lumicell System, designed to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery. The company was founded by Linda G. Griffith, David G. Kirsch, Jorge M. Ferrer, Ralph Weissleder, W. David Lee, Andrey J. Zarur, and Moungi G. Bawendi in 2008 and is headquartered in Wellesley, MA. | Chief Tech/Sci/R&D Officer | - |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | - |
Training of Felix Geissler
| Eberhard Karls Universität Tübingen | Doctorate Degree |
| University of Innsbruck | Doctorate Degree |
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CURIS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Lumicell, Inc. develops and markets image-guided cancer surgery solutions. It offers Lumicell System, designed to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery. The company was founded by Linda G. Griffith, David G. Kirsch, Jorge M. Ferrer, Ralph Weissleder, W. David Lee, Andrey J. Zarur, and Moungi G. Bawendi in 2008 and is headquartered in Wellesley, MA. | Electronic Technology |
| Sanofi Corp. |
- Stock Market
- Insiders
- Felix Geissler
